(TIL) Tumour-Infiltrating Lymphocyte Therapy Market Size to be Worth USD 2.1 Billion by 2034, at 40% CAGR: Prophecy Market Insights [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Therapy), By Indication (Indication, Hematologic Malignancies), By Source of TILs (Surgical Tumor Samples, Blood Samples), and By Regional Forecast, (2024-2034), which provides the perfect mix of market strategies, and industrial expertise with new cutting-edge technology to give the best experience. Covina, Aug. 23, 2024 (GLOBE NEWSWIRE) -- According to Prophecy Market Insights, the global tumour-infiltrating lymphocyte (TIL) therapy market size and share is projected to grow from USD 0.1 Billion in 2024 and is forecasted to reach USD 2.1 Billion by 2034 , exhibiting a compound annual growth rate (CAGR) of 40% during the forecast period (2024 - 2034). Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Report Overview Tumour-Infiltrating Lymphocyte (TIL) Therapy is an innovative and personalized form of cancer immunotherapy that harnesses the body's own immune system to combat cancer. This approach focuses on using TILs, which are a type of white blood cell found within the tum
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics (NASDAQ:IOVA) delivers shareholders favorable 74% return over 1 year, surging 4.9% in the last week alone [Yahoo! Finance]Yahoo! Finance
- 3 Things You Need to Know if You Buy Iovance Biotherapeutics Today [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics to Present at Upcoming Conferences [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics to Present at Upcoming ConferencesGlobeNewswire
- 3 Monster Biotech Stocks to Buy Before 2025 [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 8/8/24 - Beat
IOVA
Sec Filings
- 9/5/24 - Form 4
- 9/5/24 - Form 4
- 9/5/24 - Form 4
- IOVA's page on the SEC website